I'd love to put that in perspective. It's estimated at between $350 million to $600 million to bring a vaccine all the way from discovery to the end of phase three and licensure. A small smattering of this funding was offered to companies throughout Canada—through the NRC, for instance, a maximum of $5 million to get to the end of phase one. That really put the major part of the burden of development on the companies themselves.
To finish your question, yes, I think if we had received upfront funding at the beginning—and Gary sounds as though he has a fantastic solution as well—we'd be well into phase three toward licensure by now.